UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 9, 2007
KEMET Corporation
(Exact name of registrant as specified in its charter)
Delaware |
0-20289 |
57-0923789 |
(State or other jurisdiction) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
2835 KEMET Way, Simpsonville, SC |
29681 |
|
(Address of principal executive offices) |
(Zip Code) |
|
|
|
|
Registrants telephone number, including area code: (864) 963-6300 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CRS 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4c))
Item 2.01 Completion of Acquisitions or Disposition of Assets
On March 9, 2007, KEMET Corporation announced that it will launch its public tender offer for all of the issued and outstanding shares in Evox Rifa Group Oyj and for all of the loan notes under the convertible capital loan issued by Evox Rifa on March 12, 2007.
A copy of the press release has been included as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(a) Not applicable
(b) Not applicable
(c) Not applicable
(d) Exhibits
99.1 Press Release, dated March 9, 2007 issued by the Company
Signature
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 9, 2007 |
KEMET Corporation |
|
|
|
/S/ D. E. Gable |
|
|
|
David E. Gable |
|
|
|
Senior Vice President and |
|
|
|
Chief Financial Officer |
2